Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis
Year: 2015
Type: article
Abstract: BACKGROUND: Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of this study is to evaluate the association between ANXA1 expression, BRCA1/2 germline carriership, specific tumor subtypes and survival in breast cancer patients. METHODS: Clinical-pathological information and follow-up data were collected from nine breast cancer studies from the Breast Cancer Association Consortium (BCAC) (n = 5,752) and from one study of familial breast cancer patients with BRCA1/2 mutations (n = 107). ANXA1 expression was scored based on the percentage of immunohistochemical staining in tumor cells. Survival analyses were performed using a multivariable Cox model. RESULTS: The frequency of ANXA1 positive tumors was higher in familial breast cancer patients with BRCA1/2 mutations than in BCAC patients, with 48.6 % versus 12.4 %, respectively; P <0.0001. ANXA1 was also highly expressed in BCAC tumors that were poorly differentiated, triple negative, EGFR-CK5/6 positive or had developed in patients at a young age. In the first 5 years of follow-up, patients with ANXA1 positive tumors had a worse breast cancer-specific survival (BCSS) than ANXA1 negative (HRadj = 1.35; 95 % CI = 1.05-1.73), but the association weakened after 10 years (HRadj = 1.13; 95 % CI = 0.91-1.40). ANXA1 was a significant independent predictor of survival in HER2+ patients (10-years BCSS: HRadj = 1.70; 95 % CI = 1.17-2.45). CONCLUSIONS: ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and correlated with poor prognosis features: triple negative and poorly differentiated tumors. ANXA1 might be a biomarker candidate for breast cancer survival prediction in high risk groups such as HER2+ cases.
Source: BMC Medicine
Authors: Marcelo Sobral-Leite, Jelle Wesseling, Vincent T. H. B. M. Smit, Heli Nevanlinna, Martine H. van Miltenburg, Joyce Sanders, Ingrid Hofland, Fiona M. Blows, Penny Coulson, Gazinska Patrycja, Jan H. M. Schellens, Rainer Fagerholm, Päivi Heikkilä, Kristiina Aittomäki, Carl Blomqvist, Elena Provenzano, Hamid Raza Ali, Jonine Figueroa, Mark Sherman, Jolanta Lissowska, Arto Mannermaa, Vesa Kataja, Veli-Matti Kosma, Jaana M. Hartikainen, Kelly-Anne Phillips, kConFab/AOCS Investigators, Fergus J. Couch, Janet E. Olson, Celine Vachon, Daniel Visscher, Hermann Brenner, Katja Butterbach, Volker Arndt, Bernd Holleczek, Maartje J. Hooning, Antoinette Hollestelle, John W. M. Martens, Carolien H. M. van Deurzen, Bob van de Water, Annegien Broeks, Jenny Chang-Claude, Georgia Chenevix-Trench, Douglas F. Easton, Paul D. P. Pharoah, Montserrat García-Closas, Marjo de Graauw, Marjanka K. Schmidt
Institutions: The Netherlands Cancer Institute, Instituto Nacional de Câncer - INCA, Leiden University Medical Center, University of Helsinki, Helsinki University Hospital, University of Cambridge, Institute of Cancer Research, Utrecht University, Cancer Research UK, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, National Institutes of Health, Division of Cancer Epidemiology and Genetics, National Cancer Institute, The Maria Sklodowska-Curie National Research Institute of Oncology, University of Eastern Finland, Kuopio University Hospital, Central Finland Health Care District, The University of Melbourne, Peter MacCallum Cancer Centre, St Vincent's Hospital Melbourne, Mayo Clinic, German Cancer Research Center, Deutsches Konsortium für Translationale Krebsforschung, Krebsregister Saarland, Erasmus MC Cancer Institute, Leiden University, QIMR Berghofer Medical Research Institute
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,095
Funders: U.S. Department of Health and Human Services, Breast Cancer Research Foundation, Helsingin ja Uudenmaan Sairaanhoitopiiri, David F. and Margaret T. Grohne Family Foundation, Francis Crick Institute, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Cancer Research UK, National Institute for Health and Care Research, Academy of Medical Sciences, University of Cambridge, National Breast Cancer Foundation, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Kuopion Yliopistollinen Sairaala, Peter MacCallum Cancer Centre, Royal Adelaide Hospital, Townsville Hospital and Health Service, National Institutes of Health, Medical Research Council, National Health and Medical Research Council, National Cancer Institute
Awards: A genome-wide association study for breast cancer in BRCA1 mutation carriers, G1357738703, G1616122786, G1619738472, G1699944494, G1707237230, G1998022053, G2029883983, G2161821489, G2202675246, G236237718, G240531469, G2514702731, G2613824078, G2731186574, G2806700688, G2899816875, G2920252501, G2953759644, G3003753785, G3177576377, G3182923297, G3217666617, G3387589778, BRCA2 missense mutations and breast cancer, G348758045, G3849703175, G3891343362, G389926461, G3919799492, G3983849296, G4014247827, G4197410787, G424082930, G431899019, G4333708648, G4374987959, G4557758420, G4645104295, G4662672464, G4751904517, G4893741037, G5025971311, G5121539642, G5177488513, G529633706, G533195186, G5645629167, G5706291357, G6122886370, G6195211026, G6200275587, G6208597191, G6229591247, G6254892548, G6283257732, G6536232728, G6552302344, G6554607497, G6861363268, G6903117160, G6919029964, G7009610138, G704544610, G7088314342, G7116997479, G7149073, G7242219286, G7288270010, G7378152860, G7383316951, G7410254275, BRCA1 and BRCA2 missense mutations and breast cancer risk, G7707586391, Identifying and validating novel susceptibility genes for breast cancer, G8453733030, G8611704976, G8743198496, G8975197756, G897858774, G9000101281, Mayo Clinic Breast Cancer SPORE, G969318568
OpenAlex ID: W1497435151